Abdi Ibrahim Pharmaceuticals
June 23, 2026
Theater 3
Type: Company Presentation
Focus Area:
Oncology
Abdi İbrahim Pharmaceuticals is Turkey’s leading pharmaceutical company with more than 24 years of market leadership, operations in over 70 countries, and approximately USD 1,1 billion in annual revenue. Through its biologics arm, AbdiBio, the company offers fully integrated biologics development and manufacturing capabilities from cell line development to finished drug product. AbdiBio operates a GMP-approved biomanufacturing facility with commercial-scale single-use bioreactor capacity and expertise in biosimilar development, analytical characterization, fill & finish, regulatory support, and global supply. The company is currently advancing a late-stage pembrolizumab biosimilar program aligned with EU and US loss-of-exclusivity timelines.
Company HQ City:
Istanbul
Company HQ State:
Maslak
Company HQ Country:
Turkey
Year Founded:
1912
Lead Product in Development:
Pembrolizumab
CEO
Süha Taşpolatoğlu
Development Phase of Lead Product
Phase I
Number of Unlicensed Products Looking for Licensing
1
When you expect your next catalyst update?
Q2 2026 / June 2026
What is your next catalyst (value inflection) update?
Completion of clinical batch manufacturing, Phase I study initiation, and regulatory interactions for the pembrolizumab biosimilar program.
Abdi İbrahim has received scientific advice from both the U.S. Food and Drug Administration and the European Medicines Agency regarding the development of its pembrolizumab biosimilar candidate, mAbdi2. Both agencies found the company’s proposed streamlined clinical development plan adequate to support a future Biologics License Application (BLA).The development strategy includes a single clinical trial and does not require a Phase III study. A clinical batch has already been manufactured, and a global clinical trial is planned to begin with first patient in (FPI) in Q3 2026.
This timeline is designed to enable product launch aligned with the loss of exclusivity for pembrolizumab in key markets—November 2029 in the United States and January 2031 in the European Union.
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}